Ipraalox

Pantoprazole, the active ingredient in Ipraalox, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It treats acid‑related disorders such as gastro‑oesophageal reflux disease and is prescribed for adult patients. GNH USA supplies Ipraalox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Pantoprazole is a proton pump inhibitor that reduces gastric acid secretion in several acid‑related conditions. - Gastro‑oesophageal reflux disease: provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive esophagitis: accelerates mucosal healing and reduces further erosion. - Peptic ulcer disease: supports ulcer healing and prevents recurrence. - Helicobacter pylori eradication regimens: enhances the effectiveness of antibiotic‑based therapy.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild, transient headache. - Diarrhoea: loose stools without blood. - Nausea: mild stomach upset. - Abdominal pain: cramping or discomfort. - Flatulence: increased gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhoea. - Low magnesium levels: muscle cramps, irregular heartbeat. - Liver enzyme elevation: asymptomatic rise in ALT/AST. - Fracture risk: decreased bone mineral density with long‑term use.

When using Pantoprazole, consider the following precautions: - Assess renal function: adjust use if severe impairment is present. - Monitor for infections: be alert for signs of C. difficile infection. - Evaluate magnesium status: periodic testing is advised for long‑term therapy. - Review bone health: consider calcium/vitamin D supplementation if therapy exceeds 12 months. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantaprazole may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Antifungal azoles (e.g., ketoconazole): reduced absorption of the azole. - HIV protease inhibitors: decreased efficacy of the antiviral. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR values. - Methotrexate: increased serum levels. - Digoxin: possible rise in serum digoxin concentrations. - Phenytoin: altered metabolism of the anti‑epileptic.